Supernus Pharmaceuticals Inc (SUPN)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	0	0	400,382	379,252	374,788	370,383	366,038	361,751	357,521	353,349	349,232	345,170	341,163	337,210	333,310
Total stockholders’ equity	US$ in thousands	1	912,191	919,908	912,150	0	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383	595,428	557,257	522,904	480,018
Debt-to-equity ratio		0.00	0.00	0.00	0.00	—	0.00	0.00	0.48	0.46	0.46	0.47	0.49	0.49	0.50	0.53	0.57	0.58	0.61	0.64	0.69

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1K
= 0.00

The debt-to-equity ratio for Supernus Pharmaceuticals Inc has shown a declining trend over the most recent quarters, indicating that the company has been using less debt relative to equity to finance its operations. In Q4 2022, the ratio was 0.45, which increased slightly to 0.47 and 0.48 in Q3 2022 and Q2 2022, respectively. However, in Q1 2023, there was a significant jump in the ratio to 0.53, suggesting an increase in the company's reliance on debt for financing.

Subsequently, in the most recent quarters, Q2 2023, Q3 2023, and Q4 2023, the debt-to-equity ratio decreased to 0.00, indicating that the company has either paid off its debt or increased its equity position significantly. Overall, the declining trend in the debt-to-equity ratio reflects a strengthening financial position for Supernus Pharmaceuticals Inc as it has reduced its debt burden and improved its equity base.